Thus, we suggest that embryo-derived TAMs (Tim-4+) and peripheral monocyte–derived TAMs (Tim-4–) are biologically different in peritoneal ovarian cancer progression, and specifically targeting Tim-4+ (but not Tim-4–) TAMs may be therapeutically beneficial to control ovarian cancer and/or other types of cancer peritoneal metastasis and progression. This evidence concerns the gene TIMD4 and cancer.